Cytogenetic abnormalities sufficient for diagnosis of AML with myelodysplasia-related changes when 20% or more PB or BM blasts are present
| Complex karyotype* Unbalanced abnormalities | Balanced abnormalities |
| −7 or del(7q) | t(11;16)(q23;p13.3)† |
| −5 or | t(3;21)(q26.2;q22.1)† |
| i(17q) or t(17p) | t(1;3)(p36.3;q21.1) |
| −13 or del(13q) | t(2;11)(p21;q23)† |
| del(11q) | t(5;12)(q33;p12) |
| del(12p) or t(12p) | t(5;7)(q33;q11.2) |
| del(9q) | t(5;17)(q33;p13) |
| idic(X)(q13) | t(5;10)(q33;q21) |
| t(3;5)(q25;q34) |
| Complex karyotype* Unbalanced abnormalities | Balanced abnormalities |
| −7 or del(7q) | t(11;16)(q23;p13.3)† |
| −5 or | t(3;21)(q26.2;q22.1)† |
| i(17q) or t(17p) | t(1;3)(p36.3;q21.1) |
| −13 or del(13q) | t(2;11)(p21;q23)† |
| del(11q) | t(5;12)(q33;p12) |
| del(12p) or t(12p) | t(5;7)(q33;q11.2) |
| del(9q) | t(5;17)(q33;p13) |
| idic(X)(q13) | t(5;10)(q33;q21) |
| t(3;5)(q25;q34) |
Three or more unrelated abnormalities, none of which are included in the ″AML with recurrent genetic abnormalities″ subgroup; such cases should be categorized in the appropriate cytogenetic group.
These abnormalities most commonly occur in therapy-related disease, and therapy-related AML should be excluded before these are used as evidence for diagnosis of AML with myelodysplasia-related changes.